Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
Demo Company
GLOBETECH PUBLISHING LLC

Upgrades Enhance Dedicated Protein Purification System

By BiotechDaily International staff writers
Posted on 22 May 2013
A flexible and easily customizable protein purification system was designed to enable investigators to automate laborious and repetitive protein purification steps and allow them to concentrate on research applications of the purified sample.

The GE Healthcare (Uppsala, Sweden) ÄKTA Pure Protein Purification System is a flexible and intuitive chromatography platform for fast purification of proteins, peptides, and nucleic acids from microgram to gram levels of target product.

The latest generation of the ÄKTA Pure System boasts a new fraction collector that is covered to minimize contamination and supports flexible combinations of collection vessels from deep-well plates to 250 mL bottles.

In addition, a novel sample pump provides fast, automated, and complete loading of up to seven samples. The pump's integrated air-sensor detects the final drop of sample, automatically preventing the introduction of air while ensuring the complete sample reaches the column. The sample pump also has a robust wash program that removes any air introduced between samples.

The ÄKTA Pure Systems may be customized quickly and easily due to the modular design of both its hardware and software components. The operator is able to choose from more than 20 proven hardware options, and the system may be extended further by interfacing third-party add-ons such as detectors and autosamplers.

Related Links:

GE Healthcare



Channels

Genomics/Proteomics

view channel
Image: An activated PTEN dimer that contains two non-mutant proteins (A) can transform the functional lipid (D) on the cellular membrane (E) into a chemical form that tunes down cancer predilection. Dimers that contain a mutated protein (B) or PTEN monomers cannot transform the functional lipid (Photo courtesy of Carnegie Mellon University).

PTEN Requires a Stable Dimer Configuration to Effectively Suppress Tumor Growth

Molecular structural analysis has shown that the PTEN (phosphatase and tensin homolog) tumor suppressor can function effectively only when two wild-type alleles are present to form a stable dimer that... Read more

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.